Long-term COVID-19 Immune Response in a Vulnerable Neighbourhood in Argentina
NCT04673279 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 189
Last updated 2021-08-25
Summary
Between June 10t h and July 1st, a cross-sectional design study in an Argentina slum, showed a prevalence based on immunoglobuling G-class (IgG) antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) of 53.4%. It remains unanswered whether natural infection produces sustained antibodies. The aim of this study is to evaluate the presence of IgG antibodies for Coronavirus disease 2019 (COVID-19) after 5 months in inhabitants of Barrio 31 who consented the Seroprevalence Study for COVID-19.
Conditions
- Coronavirus Disease 2019
Interventions
- DIAGNOSTIC_TEST
-
serology
An enzyme linked immunosorbent assay (ELISA) developed and validated in Argentina which detects antibodies against two viral antigens, trimeric spike and the receptor binding domain (RBD) of the spike protein.
Sponsors & Collaborators
-
Hospital de Niños R. Gutierrez de Buenos Aires
collaborator OTHER -
Ministerio de Salud GCBA
collaborator UNKNOWN -
Hospital Italiano de Buenos Aires
lead OTHER
Principal Investigators
-
Vanina Pagotto, MD MG · Hospital Italiano de Buenos Aires
-
Alicia Mistchenko, Phd · Hospital de Niños Ricardo Gutierrez
-
Silvana Figar, MD MG · Hospital Italiano de Buenos Aires
-
Andrea Gamarnick, Phd · National Council of Scientific and Technical Research, Argentina
-
Ana Maria Gomez Saldaño, MD MG · Salud Comunitaria Ministerio de Salud del Gobierno de la Ciudad de Buenos Aires
-
Lorena Luna · Salud Comunitaria Ministerio de Salud del Gobierno de la Ciudad de Buenos Aires
-
Julieta Salto · Salud Comunitaria Ministerio de Salud del Gobierno de la Ciudad de Buenos Aires
-
Magdalena Wagner Manslau · Salud Comunitaria Ministerio de Salud del Gobierno de la Ciudad de Buenos Aires
-
Fernan Quiroz, MD MG · Ministerio de Salud del Gobierno de la Ciudad de Buenos Aires
Eligibility
- Min Age
- 14 Years
- Max Age
- 90 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-12-02
- Primary Completion
- 2021-08-20
- Completion
- 2021-08-20
Countries
- Argentina
Study Locations
More Related Trials
-
Serologic Profile of SARS CoV2 in COVID-19 Patients With Systemic Diseases
NCT04530461 ·Status: UNKNOWN
-
Immune Mediators and Metabolites to Stratify Systemic Lupus Erythematosus Patients at High Risk of Cardio Vascular Diseases
NCT04276701 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Pre-exposure Prophylaxis of SARS-CoV-2 Infection (COVID-19) by Monoclonal Antibodies with Early Access Authorization in Immunocompromised Patients. a Prospective Cohort.
NCT05216588 ·Status: COMPLETED
-
Evaluation of Prevalence and Risk Factors of Persistent COVID-19 in Immunocompromised Patients
NCT06576102 ·Status: ACTIVE_NOT_RECRUITING
-
Study of Neonatal IgG Fc Receptor Expression in Natural Killer T Cells Expressing an Invariant T Receptor : Implication in the Pathophysiology of Systemic Lupus
NCT05859191 ·Status: RECRUITING
-
Role of the Neonatal Fc Receptor for IgG in the Pathophysiology of Lupus
NCT03896373 ·Status: COMPLETED
-
The Relationship Between COVID-19 and Autoimmune Diseases, Lessons From Practice
NCT04558203 ·Status: COMPLETED
-
Argentinian Prospective Registry of Patients With Lupus
NCT05470569 ·Status: RECRUITING
-
Security Efficacy COVID-19 Vaccination
NCT05743361 ·Status: COMPLETED
-
The Genital Tract Microflora in Women With Systemic Lupus Erythematosus (SLE) and Immunoglobulin A (IgA) Nephropathy.
NCT05132621 ·Status: UNKNOWN
-
A Study of CAR-T Cells in Subjects With Systemic Lupus Erythematosus
NCT06900764 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Long-Term Outcomes in SLE at Peking University People's Hospital
NCT07005479 ·Status: RECRUITING
-
Gut Microbiota Dysbiosis in Lupus Nephritis
NCT06231303 ·Status: NOT_YET_RECRUITING
-
Catalytic Antibodies and Lupus in Martinique
NCT01157468 ·Status: COMPLETED
-
A Clinical Study of CD19 Universal CAR-γδT Cells in Active Systemic Lupus Erythematosus
NCT06106893 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Prediction of Outcome of Lupus Nephritis
NCT02403115 ·Status: UNKNOWN
-
Premature Atherosclerosis in Systemic Lupus Erythematosus
NCT04037293 ·Status: UNKNOWN
-
Serum Prevalence of SARS-Cov-2 Antibodies in Pre-pandemic Blood Samples (SPARE)
NCT04712448 ·Status: ACTIVE_NOT_RECRUITING
-
Highly Sensitive Serum Cardiac Troponin T and Cardiovascular Events in Patients With Systemic Lupus Erythematosus
NCT04580108 ·Status: COMPLETED
-
The Diagnostic Utility of T Immunoglobulin G and T Immunoglobulin M Biomarkers in Patients With Systemic Lupus Erythematosus Disease : Associations With Disease Activity and Damage
NCT07136337 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Anti-ficolin-3 Antibodies in Lupus Nephritis
NCT03842787 ·Status: COMPLETED
-
Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases
NCT06828042 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Immunome Project Consortium for Autoinflammatory Disorders
NCT03919110 ·Status: COMPLETED
-
Clinico-biological Collection to Investigate the Physiopathology of Systemic Autoimmune Diseases
NCT05251415 ·Status: RECRUITING
-
Next Generation Pathogen Sequencing for Prediction of Infection in Rheumatic Disease
NCT04226261 ·Status: UNKNOWN